OSE Immunotherapeutics and the FoRT Foundation Announce Completion of Enrollment in Combi-TED, a Phase 2 Clinical Trial Evaluating Tedopi® in Combination with Nivolumab or Docetaxel in Patients with Non-Small Cell Cancer

Core Viewpoint - OSE Immunotherapeutics and the FoRT Foundation have completed patient enrollment in the Combi-TED Phase 2 clinical trial, which evaluates the therapeutic cancer vaccine Tedopi® in combination with nivolumab or docetaxel for patients with Non-Small Cell Lung Cancer (NSCLC) [1][4][8] Group 1: Clinical Trial Details - The Combi-TED trial is an open-label, randomized, three-arm Phase 2 study involving 105 HLA-A2 positive patients with metastatic NSCLC who have not shown evidence of EGFR mutations or ALK or ROS1 rearrangement after first-line treatment [3][8] - The primary endpoint of the trial is the 1-year survival rate, with results expected in the second half of 2026 [3][8] - The trial is sponsored by the FoRT Foundation and conducted across sites in Italy, France, and Spain [2] Group 2: Expert Commentary - Dr. Federico Cappuzzo, Chief Investigator, expressed optimism about the trial's completion, highlighting the potential of Tedopi® to enhance the effectiveness of checkpoint inhibitors or chemotherapy [4] - Silvia Comis, Chief Clinical and Medical Research Officer, noted that the trial represents a significant step in evaluating innovative second-line treatment combinations for NSCLC [5] Group 3: Company Background - OSE Immunotherapeutics is focused on developing first-in-class therapies in immuno-oncology and immuno-inflammation, aiming to address unmet patient needs [6] - The company collaborates with leading academic institutions and biopharmaceutical companies to develop transformative medicines for serious diseases [6]